Based on known associations between inflammasome activation and cardiovascular and pulmonary outcomes,47–49 our findings suggest a critical role of abnormal expression of IL-18 during COVID-19-associated cardiopulmonary damage. The gene discussed is IL18; the disease is COVID-19.